16S

MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

Retrieved on: 
Thursday, June 2, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, OTU, Life, Lymphatic system, CIMON, Biomarker, Prognosis, Achievement, Company, Sorbonne University, Program, Science, Graft-versus-host disease, Euronext Paris, IPO, European Medicines Agency, Survival, University of Toulouse, 16S, Forward-looking statement, CEO, Immunity, AML, Dysbiosis, Otus, AE, Gastroenteritis, MET, Hematopoietic stem cell transplantation, Patient, Acute myeloid leukemia, Immune system, SAE, CGMP, Population, Hospital, Infection, Operational taxonomic unit, Bacteria, Principal, AP-HP, Scientific Advice Mechanism, Hematology, Capsule, Cancer, Safety, HRMS, Pharmaceutical industry

The topline results also show rapid and persistent engraftment of MaaT033 in the patients gut.

Key Points: 
  • The topline results also show rapid and persistent engraftment of MaaT033 in the patients gut.
  • Todays announcement confirms previously-announced promising interim results of the trial, which allowed early completion of the study.
  • Together with a good safety profile, this solid evidence for our first oral candidate is a crucial milestone for MaaT Pharma, commented Herv Affagard, CEO and co-founder of MaaT Pharma.
  • This strong foundational data supports the launch of the next phase evaluating MaaT033 in preventing allo-HSCT complications in this patient population.

MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study

Retrieved on: 
Monday, January 24, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biomarker, Euronext Paris, Survival, Forward-looking statement, Patient, Human, Degenerative disease, Safety, Incidence, MET, CIMON, OTU, Operational taxonomic unit, Maat, CEO, Data monitoring committee, Acute myeloid leukemia, Bacteria, Graft-versus-host disease, Enema, Company, 16S, CGMP, MD, Capsule, Cancer, Pharmaceutical industry, Dietary supplement, Antibiotics, MaaT033, MaaT Pharma, MAAT033, MAAT PHARMA

Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.

Key Points: 
  • Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.
  • These interim results are an important milestone for MaaT Pharma as MaaT033 is our second drug candidate and our first oral formulation, to demonstrate proof of engraftment in humans, said Herv Affagard, CEO and co-founder of MaaT Pharma.
  • MaaT033 is intended to improve survival outcomes in hemato-oncology patients receiving allo-HSCT by protecting and restoring their gut microbiome.
  • We look forward to further exploring the data from CIMON and preparing for a Phase 2/3 trial start.